Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- association label "The observed efficacy of antidepressants as treatment for bulimia nervosa led to trials to evaluate their effect on binge eating disorder. Antidepressants that have shown promising results include bupropion, duloxetine, escitalopram, fluvoxamine, fluoxetine, imipramine, sertraline and venlafaxine" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- context label "Adults" assertion.
- association label "SSRIs including paroxetine, fluoxetine and escitalopram have been found as effective treatment for patients with premature ejaculation (Arafa and Shamloul, 2007). Premature ejaculation is also treated with clomipramine and sertraline (Balon, 1996; McMahon, 1998), as well as with dapoxetine, a member of the SSRI family, which is however not used to treat depression (Andersson et al., 2006)" assertion.
- context label "Adults" assertion.
- association label "Solid evidence justifies also uses of antidepressants for lessening hot flashes during menopause. This includes citalopram (Barton et al., 2010), escitalopram (LaCroix et al., 2012), paroxetine (Stearns et al., 2003) and desvenlafaxine" assertion.
- HP_0031217 label "hot flashes" assertion.
- HP_0031217 label "hot flashes" assertion.
- HP_0031217 label "hot flashes" assertion.
- HP_0031217 label "hot flashes" assertion.
- context label "Adults" assertion.
- association label "Solid evidence justifies also uses of antidepressants for lessening hot flashes during menopause. This includes citalopram (Barton et al., 2010), escitalopram (LaCroix et al., 2012), paroxetine (Stearns et al., 2003) and desvenlafaxine" assertion.
- context label "Adults" assertion.
- association label "Solid evidence justifies also uses of antidepressants for lessening hot flashes during menopause. This includes citalopram (Barton et al., 2010), escitalopram (LaCroix et al., 2012), paroxetine (Stearns et al., 2003) and desvenlafaxine. *Table 2 specifies venlafaxine as well" assertion.
- context label "Adults" assertion.
- association label "Solid evidence justifies also uses of antidepressants for lessening hot flashes during menopause. This includes citalopram (Barton et al., 2010), escitalopram (LaCroix et al., 2012), paroxetine (Stearns et al., 2003) and desvenlafaxine" assertion.
- DB06700 label "Desvenlafaxine" assertion.
- context label "Adults" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- association label "Although antidepressants are not the first-line prophylactic strategy for patients with migraine, several clinical trials have proven their effectiveness in the treatment of migraine and related headache disorders (Koch and Jurgens, 2009). Especially TCAs: amitriptyline (Couch and Hassanein, 1979; Jackson et al., 2010; Kalita et al., 2013) and nortriptyline (Holroyd et al., 2001; Jackson et al., 2010) have the best evidence for use in migraine prevention. When amitriptyline is not tolerated by patients, treatment is continued with nortriptyline (Burch, 2019)." assertion.
- context label "Adults" assertion.
- association label "Drugs from all five classes of antidepressants have been investigated for use as smoking cessation aids (Shoaib and Buhidma, 2018). The second generation TCA nortriptyline is regarded as the most promising alternative to bupropion. This antidepressant mainly inhibits noradrenaline and serotonin transporters (Kripke, 2005). Antidepressants of the SSRI category are not effective, however, suggesting that serotonin does not play the main role in smoking addiction (Hughes et al., 2014)." assertion.
- context label "Adults" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2 contains information on trazodone and mirtazapine). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- association label "Among TCAs, doxepin (sinequan) appears to be best suited for managing insomnia in healthy adults. Doxepin works as a selective antagonist to H(1) receptors, which promote the initiation and maintenance of sleep (Owen, 2009) (Table 2 contains information on trazodone and mirtazapine). Ultra-low doses of this drug (< 6 mg per day) significantly improve and sustain both maintenance and duration of sleep (Rojas-Fernandez and Chen, 2014; Weber et al., 2010). Another frequently prescribed TCA is amitriptyline, which as a long-term option is found to be effective for patients with ongoing sleep problems (Everitt et al., 2014; Pagel and Parnes, 2001)." assertion.
- context label "Adults" assertion.
- association label "(Osland et al., 2018; Otasowie et al., 2014) information extracted from Table 2." assertion.
- context label "Adults" assertion.
- association label "The SGA olanzapine is considered the most appropriate, followed by quetiapine and aripiprazole. Although off-label prescription of SGAs represents a common clinical practice in accordance with a worldwide trend, the use of long-acting injection formulations was considered inappropriate by 69% of psychiatrists in our sample. Attitudes on off-label use of Aripiprazole in the treatment of BPD: Highly inappropriate = 44 (21.8%); Innapropriate = 38 (18.8%); Doubt = 74 (36.6%); Appropriate = 43 (21.3%); Highly appropriate = 3 (1.5%)" assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Asenapine in the treatment of BPD: Highly inappropriate = 97 (48.0%); Innapropriate = 24 (11.9%); Doubt = 60 (29.7%); Appropriate = 21 (10.4%); Highly appropriate = 0 (0%)" assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Clozapine in the treatment of BPD: Highly inappropriate = 115 (56.9%); Innapropriate = 32 (15.8%); Doubt = 42 (20.9%); Appropriate = 13 (6.4%); Highly appropriate = 0 (0%)" assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Paliperidone in the treatment of BPD: Highly inappropriate = 81 (40.1%); Innapropriate = 32 (15.8%); Doubt = 66 (32.7%); Appropriate = 20 (9.9%); Highly appropriate = 3 (1.5%)" assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Risperidone in the treatment of BPD: Highly inappropriate = 51 (25.2%); Innapropriate = 31 (15.3%); Doubt = 90 (44.6%); Appropriate = 28 (13.9%); Highly appropriate = 2 (1.0%)" assertion.
- context label "Adults" assertion.
- association label "Attitudes on off-label use of Ziprasidone in the treatment of BPD: Highly inappropriate = 167 (82.7%); Innapropriate = 12 (5.9%); Doubt = 18 (8.9%); Appropriate = 5 (2.5%); Highly appropriate = 0 (0%)" assertion.
- context label "Adults" assertion.
- association label "Hence, it is possible that its popularity in special populations is due to the fact that the unpleasant or unwanted effects of addiction substances are somehow soothed by quetiapine. Currently, quetiapine is tested in substance use disorders, showing some promise, but it is likely to be misused in certain contexts" assertion.
- context label "Adults" assertion.
- association label "This involves also off-label prescription of the drug as hypnotic, which is high, and this has been attributed to the off-label promotion of its prescription by its manufacturers, who were also fined for this (Monasterio & McKean, 2011a, 2011b; McKean & Monasterio, 2012); this probably ensued in increased demand for other than indicated conditions (Monasterio & McKean, 2013a)." assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "The on‐label indication for Brintellix is depression; we identified the following off‐label indications: schizophrenia, episodic mood disorders, anxiety disorders, personality disorders, bipolar depression, post‐traumatic stress disorder, and chronic pain." assertion.
- context label "Adults" assertion.
- association label "In addition to neuropathic pain, bupropion has also shown some effectiveness in treating chronic pain that is caused by inflammatory bowel disease (IBD)" assertion.
- context label "Adults" assertion.
- association label "Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRIs) that has been used for managing depression. It has also widely been studied as a pharmacological option for the treatment of chronic pain conditions" assertion.
- context label "Adults" assertion.
- association label "One study has shown that although duloxetine’s role in treating somatic physical pain is unclear, the greatest effects may come from the treatment of the mental symptoms in fibromyalgia" assertion.
- context label "Adults" assertion.
- association label "Milnacipran is not currently FDA approved for the treatment of major depression. However, this is a frequent off-label application both within the USA and internationally." assertion.
- context label "Adults" assertion.
- association label "With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%." assertion.
- context label "Adults" assertion.
- association label "For maintenance treatment of BD, off-label asenapine was considered appropriate by 45% of the psychiatrists, followed by long-acting aripiprazole and olanzapine pamoate, which were considered appropriate by 37.1% and 23.8%, respectively. In summary, ~50% of Italian psychiatrists frequently (very often or often) prescribe SGAs for off-label indications." assertion.
- context label "Adults" assertion.
- association label "With regard to the use of specific SGAs in BD, off-label aripiprazole was considered appropriate for depressive episodes by 46% of the psychiatrists, followed by olanzapine which was considered appropriate by 33.7%." assertion.
- context label "Adults" assertion.
- association label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment" assertion.
- context label "Adults" assertion.
- association label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment" assertion.
- context label "Adults" assertion.
- association label "When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment" assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.
- association label "The off label antipsychotic treatments we considered were sulpiride, olanzapine, pimozide, quetiapine, risperidone, haloperidol, tiapride, chlorpromazine, and aripiprazole. We estimated the effect of antipsychotics as a group, and also estimated effects of certain individual antipsychotic chorea drugs (i.e. olanzapine, risperidone, and tiapride) commonly taken in our cohort." assertion.
- context label "Adults" assertion.